Serina Therapeutics, Inc. (SER) SEC filings document a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology and SER-252 for advanced Parkinson’s disease. The company’s filings cover quarterly financial reports, material event reports, securities registration statements, governance matters, financing agreements, and clinical-program updates.
For biotechnology investors, Serina’s 10-Q quarterly reports are useful for reviewing research and development activity, warrant liabilities, stockholders’ equity matters, related-party disclosures, and financing instruments. Material event filings have disclosed SER-252 study updates, Safety Monitoring Committee review, cohort advancement, financial results releases, employment agreements, director appointments, annual meeting voting results, and amendments to authorized share capital.
Registration statements and related 8-K filings provide detail on common stock purchase agreements, resale registration matters, selling stockholder arrangements, and potential issuance of common stock. Annual reports on Form 10-K, when available, are important for reviewing risk factors, business descriptions, liquidity discussion, executive compensation references, and audited financial statements. Insider transaction filings on Form 4 are relevant for tracking reported purchases, sales, grants, and other ownership changes by company insiders.
Key SER filing topics include the SER-252 advanced Parkinson’s disease program, POZ Platform research and development, financing capacity, equity-linked instruments, governance actions, and the company’s reported segment related to POZ platform research and development.
Form 4 snapshot – Serina Therapeutics (SER): On 07/21/2025 Chief Scientific Officer Randall Moreadith exercised 6,500 fully-vested options at an exercise price of $0.06 and immediately sold the same 6,500 common shares in the open market. The weighted-average sale price was $5.34 (range $5.31-$5.40), generating gross proceeds of roughly $34.7 k and eliminating his direct common-stock position, which now stands at 0 shares. He retains 495,186 options after the transaction. The filing reflects a routine option-exercise-and-sell pattern rather than large-scale disposal, but it does reduce immediate share ownership by a named executive.